Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

Merck & Co., Inc.Trade
Vanguard International High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? Merck & Co., Inc. trades at $132.79 (market cap $321.77B), while Vanguard International High Dividend Yield ETF trades at $104.48. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals.

MRKVYMI
Market Cap
$321.77B
Sector
HealthBroad Market / Factor
52-Week High
$131.84$105.05
52-Week Low
$77.60$82.92
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Vanguard International High Dividend Yield ETF

VYMI trades at $104.69, up 0.1% on the day, with strong technical momentum as it approaches resistance at $105. The ETF has gained attention for its international dividend strategy, offering a 3.4% yield and delivering 55% total returns since previous coverage. Recent institutional buying and positive media sentiment highlight growing investor interest in international high-yield exposure.

The outlook remains positive given Vanguard's projection of international developed-market stocks outperforming US markets over the next decade. Key opportunities include diversification benefits and strong dividend growth, while risks center on currency fluctuations and global economic volatility. The ETF's technical strength and fundamental appeal support a constructive view for income-focused investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Vanguard International High Dividend Yield ETF

VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.

Read more on VYMI